High Rate of Non Responders to Aspirin and/or Clopidogrel Treatment in the First Days Following Percutaneous Coronary Interventions: An Ex Vivo Study

Aspirin (ASA) therapy following both acute myocardial infarction (AMI) and acute coronary syndromes (ACS) has been shown to reduce the relative risk of recurrent vascular events and death. However, the inhibition of platelet function by ASA is not uniform among patients and this may be relevant for the occurrence of new ischemic events. Recently, PFA-100 (DADE Behring, USA) closure time (CT) has been suggested as a possible tool to identify ASA-resistant patients